Natural killer/T-cell lymphoma (NKTCL) is characterized by its highly aggressive nature and rapid progression. MicroRNAs (miRNAs) play key roles in the development of NKTCL. We utilized next-generation Solexa high-throughput sequencing to compare miRNA expression in the SNK-6 and YTS NKTCL cell lines with expression in normal NK cells. We found that 195 miRNAs were upregulated in the SNK-6 cells and 286 miRNAs were upregulated in the YTS cells. Based on those results, we selected six miRNAs, including miRNA-155, and confirmed their expression using real-time polymerase chain reaction. Expression of miRNA-155 was higher in SNK-6 and YKS cells than in normal NK cells. We next determined the levels of miRNA-155 in the serum of healthy individuals and NKTCL patients, and correlated its expression with clinical parameters and inflammatory factors detected using enzyme-linked immunoabsorbent assays. Levels of miRNA-155 were higher in NKTCL patients’ serum than in serum from healthy individuals. miRNA-155 expression was higher in patients with stable or progressive disease (SD+PD) than in those with partial or complete remission (PR+CR). While further studies are needed to clarify the underlying molecular mechanisms, it appears miRNA-155 may be a molecular marker of NKTCL.
This study investigated the effects of miRNA-155 on malignant biological characteristics of NK/T-cell lymphoma cell lines and the possible mechanism. The expression of miRNA-155 was detected in lymphoma cell lines from different sources (SNK-6, YTS, Jurkat and DOHH2) by real-time PCR. Lentiviral vectors (pLL3.7) that could overexpress or downexpress miRNA-155 were constructed. Recombinant lentiviral particles were prepared and purified, and their titers determined. The expression of miRNA-155 in the infected SNK-6 cells and the cell proliferation were detected by PCR and CCK-8, respectively. Flow cytometry was used to determine the apoptosis of infected SNK-6 cells. The target of miRNA155 was predicted from Targetscan website. The effect of miRNA155 on FOXO3a expression was examined by Western blotting. The results showed that among the human NK/T-cell lymphoma cell lines SNK-6, YTS, Jurkat and DOHH2, the expression of miRNA-155 was highest in SNK-6. The infection efficiency of the recombinant lentivirus in SNK-6 was more than 70% at multiplicity of infection (MOI) of 100. The expression of miRNA-155 was significantly increased in SNK-6 cells infected by lentivirus vectors with high expression of miRNA-155 (4 times higher than the control group), and profoundly decreased in those infected with lentiviruses with low expression of miRNA-155. The proliferation of letivirus-infected SNK-6 cells was decreased as the expression of miRNA-155 reduced. The apoptosis rate was increased with the reduction in the expression of miRNA-155. FOXO3a was found to be a possible target of miRNA155, as suggested by Targetscan website. Western blotting showed that the expression of FOXO3a was significantly elevated in SNK-6 cells with miRNA-155 inhibition. It was concluded that reduction in miRNA-155 expression can inhibit the proliferation of SNK-6 lymphoma cells and promote their apoptosis, which may be associated with regulation of FOXO3a gene.
BackgroundPrimary liver cancer is a common clinical malignancy. Traditional Chinese medicine (TCM) is an alternative treatment for primary liver cancer. TCM effectively improves the survival rate and quality of life of patients, but high-level evidence is lacking.Patients and methodsThis study determined whether the combination of TCM and conventional cancer treatment affects the survival of liver cancer patients. Patients were selected from 5 tertiary hospitals in Henan Province. Two thousand and sixty-seven patients with primary liver cancer were included in the study for analysis. Patients who received adjunctive TCM treatment and underwent treatment for more than 1 month were classified as the TCM intervention cohort, i.e., the exposure group. Patients who did not receive adjunctive TCM treatment or who received adjunctive TCM treatment for less than 1 month were classified as the non-TCM intervention cohort, i.e., the non-exposed group. The main outcome indicators were the survival outcome and survival time of primary liver cancer patients. The propensity score inverse probability weighting method was used to balance the differences in the observed characteristics between the groups.ResultsThe primary cohort comprised 2,067 patients with primary liver cancer, including 462 patients who received adjunctive TCM treatment and 1,605 patients who did not receive adjunctive TCM treatment. Multiple logistic (binary) regression analysis results showed that adjunctive TCM treatment may reduce the mortality of primary liver cancer patients (regression coefficient = −0.82, P<0.001). The results of the Kaplan-Meier survival analysis indicated that the survival rate and median survival time of the exposure group before and after propensity score weighting were greater than those of the control group (P<0.0001). Multiple Cox regression analysis showed that adjunctive TCM treatment was an independent protective factor for survival in liver cancer patients (regression coefficient = −0.2477, hazard ratio (HR) = 0.7806, 95% confidence interval (CI) [0.6311–0.9655]), and cancer embolus was an independent risk factor (regression coefficient = 1.0546, HR = 0.3483, 95% CI [0.2831–0.4286]).ConclusionAdjuvant treatment with TCM has a protective effect on the prognosis of patients with primary liver cancer; it can reduce the mortality of primary liver cancer and prolong the survival time of patients. Cancer embolus is a risk factor that impacts the therapeutic effect of treatment in liver cancer patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.